Drug Profile
Research programme: Parkinson's disease therapeutics - FoldRx
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator FoldRx Pharmaceuticals
- Class Small molecules
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 06 Oct 2010 FoldRx has been acquired by Pfizer
- 22 Jul 2006 Preclinical trials in Parkinson's disease in USA (unspecified route)